Rabies Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Enzyme-Linked Immunosorbent Assay (ELISA),Polymerase Chain Reaction (PCR) Assay,Others), By Application (Hospitals,Diagnostic Centers,Public Health Labs,Home Care Setting), Regional Insights and Forecast to 2035

Rabies Diagnostics Market Overview

The global Rabies Diagnostics Market size is projected to grow from USD 1991.73 million in 2026 to USD 2080.76 million in 2027, reaching USD 2952.12 million by 2035, expanding at a CAGR of 4.47% during the forecast period.

The global Rabies Diagnostics Market is supported by more than 59,000 human deaths annually due to rabies and over 15 million people worldwide receiving post-exposure treatment each year, underscoring diagnostic urgency.

In the United States the Rabies Diagnostics Market sees over 6,000 confirmed animal exposure incidents annually and more than 300 human post-exposure prophylaxis (PEP) episodes per year, driving demand for rapid diagnostics.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Approximately 33% of all global rabies tests are now performed in endemic regions with high dog-bite incidence (exceeding 10,000+ bites per day in countries like India).
• Major Market Restraint: Around 29% of diagnostic laboratories cite limited funding and infrastructure in low-income regions as key barriers to adoption of advanced rabies diagnostics.
• Emerging Trends: Nearly 41% of new rabies diagnostic solutions launched between 2022-2024 incorporate multiplex PCR or portable point-of-care formats to enhance field testing capabilities.
• Regional Leadership: North America currently accounts for roughly 37% of the rabies diagnostics market in terms of expenditure on high-end diagnostic assays and test kits.
• Competitive Landscape: The top five diagnostic firms control approximately 58% of market share in the rabies diagnostics segment, focusing on human and veterinary test kits.
• Market Segmentation: Diagnostic method segmentation shows ELISA assays comprise about 42% of all tests, PCR methods about 33%, and others the remaining 25% in 2024.
• Recent Development: In 2024, more than 27% of newly validated rabies test kits were approved for both human and animal applications, enhancing cross-sector diagnostics.

Rabies Diagnostics Market Latest Trends

The Rabies Diagnostics Market Trends show rapid adoption of molecular diagnostics in high-burden regions where dog-bite incidents exceed 37 lakh (3.7 million) annually in a single country. Point-of-care rabies kits now represent nearly 18% of all new product launches in 2024, up from 10% in 2021.

Rabies Diagnostics Market Dynamics

The Rabies Diagnostics Market dynamics reflect rapid global expansion driven by rising testing demand across public-health laboratories, veterinary facilities, and hospitals handling more than 15 million annual exposures.

DRIVER

"Rising incidence of dog-mediated rabies and bite incidents"

The main driver in the Rabies Diagnostics Market is the high prevalence of animal exposures. In India alone, more than 37 lakh (3.7 million) dog-bite cases were reported in 2024, averaging over 10,000 incidents a day.

RESTRAINT

"Limited diagnostic infrastructure and high per-test costs in low-income regions"

The main restraint in the Rabies Diagnostics Industry Analysis is the lack of adequate infrastructure. Approximately 29% of laboratories in low-resource countries report insufficient equipment for advanced diagnostics like PCR.

OPPORTUNITY

"Expansion of field-deployable, multiplex diagnostics and One-Health surveillance"

One key Rabies Diagnostics Market Opportunity lies in multiplex and field-deployable diagnostics. In 2024, over 41% of new test launches featured multiplex PCR that simultaneously detects rabies and other zoonoses.

CHALLENGE

"Regulatory hurdles and sample-transport logistics in remote endemic regions"

The main challenge in the Rabies Diagnostics Market Outlook is managing regulatory complexity and specimen logistics. About 27% of new products experienced delays of 8-12 months in regulatory approval in key markets during 2023.

Rabies Diagnostics Market Segmentation

The Rabies Diagnostics Market Segmentation is structured by diagnostic type and application in this Rabies Diagnostics Market Research Report. By type the market is divided into Enzyme-Linked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR) Assay, and Others. By application the segments cover Hospitals, Diagnostic Centers, Public Health Labs and Home Care Settings.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Enzyme-Linked Immunosorbent Assay (ELISA): ELISA tests dominate the rabies diagnostics market, representing about 42% of test volumes globally in 2024. These immunoassay kits are widely used in both human and animal health sectors for antibody or antigen detection due to their cost-efficiency and ease of use.

The ELISA segment: projected at USD 910.3 million in 2025, capturing approximately 47.7% market share and expanding at a CAGR of 4.2%, dominates the global Rabies Diagnostics Market.

Top 5 Major Dominant Countries in the ELISA Segment

• United States: The United States leads the ELISA segment of the Rabies Diagnostics Market with a market size of USD 253.6 million in 2025, accounting for 27.8% share and growing at a CAGR of 4.1%.
• China: China’s ELISA segment: valued at USD 186.4 million in 2025, representing 20.5% share and expanding at a CAGR of 4.5%, is supported by over 6,000 tertiary laboratories implementing ELISA-based assays amid rising dog-bite incidents exceeding 3.7 million.
• India: India’s ELISA segment: estimated at USD 138.5 million in 2025, holding 15.2% share and advancing at a CAGR of 4.4%, benefits from expanded diagnostic networks across 2,800 public labs and 1,500 veterinary facilities.
• Germany: Germany’s ELISA segment: valued at USD 72.8 million in 2025, capturing 8.0% share and growing at a CAGR of 3.9%, is propelled by highly automated veterinary diagnostic networks and standardized serological testing in 600 specialized facilities.
• Brazil: Brazil’s ELISA segment: projected at USD 57.0 million in 2025, representing 6.3% share and expanding at a CAGR of 4.0%, is driven by canine rabies screening and mass vaccination programs covering 80% of urban areas.

Polymerase Chain Reaction (PCR) Assay: PCR assays captured approximately 33% of test volumes in 2024 and are increasingly used for high-sensitivity viral-RNA detection in both human and animal samples. Over 12,000 PCR kits were deployed globally in 2023 for rabies diagnostics.

The PCR Assay segment: valued at USD 525.6 million in 2025, representing approximately 27.6% market share and expanding at a CAGR of 5.1%.

Top 5 Major Dominant Countries in the PCR Assay Segment

• United States: The United States leads the PCR Assay segment of the Rabies Diagnostics Market with an estimated market size of USD 140.3 million in 2025, accounting for 26.7% share and advancing at a CAGR of 5.0%.
• China: China’s PCR Assay segment: valued at USD 118.0 million in 2025, representing 22.5% share and expanding at a CAGR of 5.2%, benefits from government-funded modernization of 1,200 diagnostic laboratories integrating multiplex PCR kits.
• Japan: Japan’s PCR Assay segment: estimated at USD 67.9 million in 2025, accounting for 12.9% share and increasing at a CAGR of 4.8%, driven by adoption of real-time PCR systems in more than 250 hospital-based laboratories and public-health institutions.
• India: India’s PCR Assay segment: valued at USD 59.3 million in 2025, capturing 11.3% share and growing at a CAGR of 5.1%, is supported by diagnostic expansion across 2,000 regional laboratories and 850 veterinary testing centers.
• United Kingdom: The United Kingdom’s PCR Assay segment: projected at USD 45.4 million in 2025, representing 8.6% share and advancing at a CAGR of 4.9%, is driven by increased public-sector investments in rabies reference laboratories adopting real-time PCR technologies.

Others: The ‘Others’ segment includes immunohistochemistry, fluorescent antibody tests (FAT), histologic examination and rapid point-of-care kits, and accounts for approximately 25% of diagnostic volumes in 2024.

The Others segment: valued at USD 470.6 million in 2025, accounting for approximately 24.7% market share and expanding at a CAGR of 3.6%.

Top 5 Major Dominant Countries in the Others Segment

• United States: The United States leads the Others segment of the Rabies Diagnostics Market with an estimated market size of USD 118.7 million in 2025, holding 25.2% share and advancing at a CAGR of 3.5%, supported by nationwide surveillance programs using fluorescent antibody testing across more than 350 specialized laboratories, processing wildlife and domestic animal samples for rabies confirmation and epidemiological monitoring.
• France: France’s Others segment: valued at USD 35.4 million in 2025, representing 7.5% share and expanding at a CAGR of 3.8%, is driven by veterinary research centers and national laboratories employing immunohistochemical assays for confirmatory rabies detection, enhancing cross-sector data accuracy within France’s integrated zoonotic disease surveillance systems.
• South Africa: South Africa’s Others segment: estimated at USD 34.2 million in 2025, capturing 7.3% share and growing at a CAGR of 3.9%, is supported by deployment of portable rapid immunoassay kits in over 400 rural testing centers, increasing diagnostic accessibility by 19% and strengthening wildlife surveillance through government-funded One-Health diagnostic programs.
• Australia: Australia’s Others segment: valued at USD 33.6 million in 2025, holding 7.1% share and expanding at a CAGR of 3.6%, is driven by advanced veterinary diagnostic infrastructure utilizing histopathological methods and fluorescent antibody testing, facilitating early case detection and improving laboratory efficiency across the nation’s high-biosecurity rabies control network.
• Brazil: Brazil’s Others segment: projected at USD 28.7 million in 2025, representing 6.1% share and advancing at a CAGR of 3.4%, is driven by increased adoption of rapid immunoassay kits for field surveillance, with over 250 regional labs integrating point-of-care tests that enhance canine rabies screening and support Brazil’s nationwide elimination strategy.

BY APPLICATION

Hospitals: Hospital laboratories represent nearly 45% of total rabies diagnostics test volumes globally in 2024, as major medical centers handle human exposure cases and complex animal bite incidents requiring confirmatory testing.

The Hospitals segment: projected at USD 888.4 million in 2025, accounting for 46.6% market share and expanding at a CAGR of 4.3%.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: The United States leads the Hospitals segment with a market size of USD 245.2 million in 2025, capturing 27.6% share and growing at a CAGR of 4.2%, driven by over 45,000 hospital-based diagnostic units processing approximately 300,000 rabies exposure samples annually, supported by national post-exposure prophylaxis (PEP) monitoring systems.
• China: China’s Hospitals segment: valued at USD 168.5 million in 2025, representing 19.0% share and increasing at a CAGR of 4.4%, is driven by government-funded diagnostic expansion across 6,000+ tertiary hospitals, strengthening the country’s surveillance network and integrating ELISA and PCR systems for human and animal rabies case management.
• India: India’s Hospitals segment: projected at USD 131.0 million in 2025, accounting for 14.8% share and advancing at a CAGR of 4.3%, is supported by modernization of 2,500 hospitals nationwide, each handling thousands of exposure cases annually, combining diagnostic testing with nationwide vaccination programs for improved rabies control outcomes.
• Germany: Germany’s Hospitals segment: estimated at USD 59.4 million in 2025, holding 6.7% share and growing at a CAGR of 4.0%, benefits from state-of-the-art clinical laboratories utilizing molecular diagnostic workflows, enhancing detection accuracy for imported rabies cases and maintaining standardized testing across major healthcare institutions.
• Brazil: Brazil’s Hospitals segment: valued at USD 42.3 million in 2025, capturing 4.8% share and expanding at a CAGR of 4.1%, is driven by hospital diagnostic integration with national public-health surveillance, increasing post-exposure rabies testing throughput by 18% between 2022 and 2024.

Diagnostic Centers: Diagnostic centers and outpatient imaging labs combined account for about 30% of rabies diagnostics test volumes in 2024, offering faster turnaround times and flexible access for pet exposures or minor bite incidents.

The Diagnostic Centers segment: valued at USD 532.1 million in 2025, representing 27.9% share and growing at a CAGR of 4.8%.

Top 5 Major Dominant Countries in the Diagnostic Centers Application

• United States: The United States dominates the Diagnostic Centers segment with a market size of USD 155.5 million in 2025, holding 29.2% share and increasing at a CAGR of 4.7%, driven by over 2,500 independent labs processing bite-exposure diagnostics with high-throughput ELISA and PCR systems for rapid result delivery.
• China: China’s Diagnostic Centers segment: valued at USD 116.6 million in 2025, representing 21.9% share and expanding at a CAGR of 4.9%, is supported by private diagnostic chain expansion and increasing collaborations between clinical laboratories and veterinary facilities enhancing testing accessibility across 150+ cities.
• India: India’s Diagnostic Centers segment: projected at USD 94.8 million in 2025, capturing 17.8% share and growing at a CAGR of 4.8%, benefits from the expansion of regional laboratory franchises offering point-of-care rabies diagnostics to urban and semi-urban populations nationwide.
• Germany: Germany’s Diagnostic Centers segment: estimated at USD 42.8 million in 2025, holding 8.0% share and advancing at a CAGR of 4.6%, is driven by private labs adopting digital ELISA and PCR-based diagnostic systems to streamline rabies testing across animal and human exposure cases.
• South Africa: South Africa’s Diagnostic Centers segment: valued at USD 29.9 million in 2025, representing 5.6% share and increasing at a CAGR of 4.5%, is supported by expanding private diagnostic facilities and mobile veterinary testing networks strengthening rabies surveillance coverage in endemic provinces.

Public Health Labs: Public health and reference laboratories account for approximately 20% of diagnostic volumes globally in 2024, as they lead national surveillance, confirmatory testing, and outbreak response.

The Public Health Labs segment: projected at USD 381.3 million in 2025, representing 20.0% market share and growing at a CAGR of 3.9%.

Top 5 Major Dominant Countries in the Public Health Labs Application

• United States: The United States leads the Public Health Labs segment with a market size of USD 104.2 million in 2025, accounting for 27.3% share and expanding at a CAGR of 3.8%, supported by 60+ reference laboratories under CDC performing confirmatory diagnostics for human and animal rabies surveillance programs.
• China: China’s Public Health Labs segment: valued at USD 79.6 million in 2025, representing 20.9% share and growing at a CAGR of 4.0%, benefits from expansion of national-level biosafety facilities integrating ELISA and PCR systems for human exposure validation and surveillance enhancement.
• India: India’s Public Health Labs segment: projected at USD 65.1 million in 2025, accounting for 17.1% share and advancing at a CAGR of 3.9%, is strengthened by nationwide diagnostic upgrades across 125 state-level reference labs collaborating with WHO for standardized rabies testing.
• Germany: Germany’s Public Health Labs segment: estimated at USD 30.4 million in 2025, holding 8.0% share and increasing at a CAGR of 3.7%, is driven by modernization of government laboratories focusing on enhanced sample management and cross-border disease surveillance initiatives.
• South Africa: South Africa’s Public Health Labs segment: valued at USD 21.3 million in 2025, representing 5.6% share and expanding at a CAGR of 3.6%, is supported by centralized zoonotic-disease surveillance networks improving rabies diagnostic throughput by 15% in 2024.

Home Care Setting: Home care and field testing environments contribute around 5% of global rabies diagnostic volumes in 2024, driven by development of portable rapid kits and outreach programs. Over 8 000 point-of-care kits were distributed in remote regions in 2023, and field sample processing improved by nearly 17% compared to conventional lab routes.

The Home Care Setting segment: valued at USD 104.7 million in 2025, accounting for 5.5% share and advancing at a CAGR of 5.5%, reflects rapid adoption of portable, user-friendly rapid kits for at-home or on-field rabies testing.

Top 5 Major Dominant Countries in the Home Care Setting Application

• India: India leads the Home Care Setting segment with a market size of USD 32.2 million in 2025, representing 30.8% share and expanding at a CAGR of 5.7%, driven by distribution of 20,000+ portable rapid kits across rural and high-incidence districts to enable early field detection.
• United States: The United States’ Home Care Setting segment: valued at USD 26.1 million in 2025, holding 24.9% share and increasing at a CAGR of 5.4%, is fueled by emerging at-home rabies diagnostic technologies for veterinary and pet owner use, enhancing preventive health screening.
• China: China’s Home Care Setting segment: estimated at USD 18.9 million in 2025, capturing 18.1% share and advancing at a CAGR of 5.6%, benefits from smart diagnostic initiatives promoting mobile and connected testing devices across both veterinary and rural health sectors.
• South Africa: South Africa’s Home Care Setting segment: projected at USD 8.6 million in 2025, representing 8.2% share and expanding at a CAGR of 5.3%, is supported by public health campaigns deploying rapid kits to improve accessibility in wildlife and rural monitoring programs.
• Brazil: Brazil’s Home Care Setting segment: valued at USD 7.9 million in 2025, holding 7.6% share and increasing at a CAGR of 5.2%, benefits from collaboration between government and healthcare NGOs distributing field testing kits to rural clinics for faster diagnosis and outbreak containment.

Regional Outlook for the Rabies Diagnostics Market

The Rabies Diagnostics Market regional outlook shows North America leading with about 37% of global share, supported by advanced laboratories and standardized protocols, followed by Europe at roughly 23% with strong public-health networks.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

In North America the Rabies Diagnostics Market accounts for roughly 37% of global diagnostics expenditure in 2024, driven by advanced lab infrastructure and strong public-health funding. Over 8,000 diagnostic laboratories in the U.S. and Canada conducted rabies testing in 2023, processing more than 300,000 exposure-related samples.

The North America Rabies Diagnostics Market: valued at USD 720.3 million in 2025, representing 37.8% global share and expanding at a CAGR of 4.2%, leads globally due to robust diagnostic infrastructure, wildlife rabies monitoring, and strong government-supported zoonotic disease surveillance systems across the region.

North America – Major Dominant Countries in the Rabies Diagnostics Market

• United States: The United States dominates the North American Rabies Diagnostics Market with a market size of USD 672.4 million in 2025, capturing 93.3% share and expanding at a CAGR of 4.1%, supported by over 400 public-health and veterinary laboratories performing approximately 300,000 rabies exposure tests annually, driving national testing efficiency and disease mapping precision.
• Canada: Canada’s Rabies Diagnostics Market: valued at USD 29.8 million in 2025, representing 4.1% share and increasing at a CAGR of 4.0%, benefits from strong public-sector diagnostic infrastructure with over 75 biosafety-certified laboratories operating under national rabies prevention and wildlife surveillance programs coordinated by provincial health authorities.
• Mexico: Mexico’s Rabies Diagnostics Market: estimated at USD 9.1 million in 2025, holding 1.3% share and growing at a CAGR of 4.5%, is supported by 80+ regional laboratories expanding diagnostic capacity under the national rabies elimination campaign targeting dog-mediated transmission.
• Cuba: Cuba’s Rabies Diagnostics Market: projected at USD 4.6 million in 2025, representing 0.6% share and expanding at a CAGR of 4.3%, benefits from improved laboratory infrastructure and WHO collaboration in diagnostic quality assurance for post-exposure case confirmation.
• Dominican Republic: The Dominican Republic’s Rabies Diagnostics Market: valued at USD 4.4 million in 2025, holding 0.6% share and advancing at a CAGR of 4.2%, is supported by increasing diagnostic equipment imports and public-health initiatives targeting canine rabies control in high-incidence zones.

EUROPE

Europe holds about 23% of the global Rabies Diagnostics Market as of 2024, and more than 4,500 labs across EU member states are engaged in rabies testing. Germany alone processed over 50,000 rabies–exposure samples in 2023 and increased test kit usage by roughly 14% from 2022.

The Europe Rabies Diagnostics Market: estimated at USD 495.8 million in 2025, accounting for 26.0% share and advancing at a CAGR of 3.9%, is supported by advanced veterinary networks, government surveillance, and standardized diagnostic procedures under European zoonosis prevention frameworks.

Europe – Major Dominant Countries in the Rabies Diagnostics Market

• Germany: Germany leads Europe’s Rabies Diagnostics Market with a market size of USD 112.2 million in 2025, representing 22.6% share and increasing at a CAGR of 3.8%, driven by over 600 accredited laboratories performing serological and molecular rabies testing in alignment with EU health directives.
• France: France’s Rabies Diagnostics Market: valued at USD 85.9 million in 2025, holding 17.3% share and growing at a CAGR of 3.9%, benefits from robust veterinary infrastructure, with 450+ regional diagnostic centers conducting standardized ELISA and PCR testing across zoonotic research programs.
• United Kingdom: The United Kingdom’s Rabies Diagnostics Market: estimated at USD 72.3 million in 2025, accounting for 14.6% share and expanding at a CAGR of 4.0%, is supported by national reference laboratories implementing advanced molecular detection and real-time surveillance for imported rabies cases.
• Italy: Italy’s Rabies Diagnostics Market: valued at USD 54.7 million in 2025, representing 11.0% share and increasing at a CAGR of 3.7%, benefits from veterinary diagnostic modernization, including over 250 labs equipped with ELISA and PCR assays for regional surveillance.
• Spain: Spain’s Rabies Diagnostics Market: projected at USD 46.1 million in 2025, capturing 9.3% share and growing at a CAGR of 3.6%, is driven by cross-border surveillance partnerships and rabies monitoring networks integrated within the EU’s One Health strategy.

ASIA-PACIFIC

The Asia-Pacific region is emerging as fastest-growing segment in the Rabies Diagnostics Market, accounting for approximately 28% of global test volumes in 2024. India reported over 3.7 million dog-bite incidents in 2024 and had more than 2,500 hospitals and diagnostic centres upgraded for rabies testing between 2022-2024.

The Asia-Pacific Rabies Diagnostics Market: valued at USD 371.2 million in 2025, representing 19.5% share and expanding at a CAGR of 5.0%, is driven by high dog-bite prevalence, rapid urbanization, and significant investments in public-health laboratory expansion.

Asia-Pacific – Major Dominant Countries in the Rabies Diagnostics Market

• China: China dominates the Asia-Pacific Rabies Diagnostics Market with a market size of USD 132.4 million in 2025, representing 35.7% share and expanding at a CAGR of 5.2%, supported by 6,000+ laboratories conducting nationwide diagnostic surveillance for over 3.7 million exposure cases each year.
• India: India’s Rabies Diagnostics Market: valued at USD 121.6 million in 2025, holding 32.8% share and growing at a CAGR of 5.1%, is driven by modernization of 2,800 public-health laboratories and nationwide expansion of diagnostic programs under government rabies control missions.
• Japan: Japan’s Rabies Diagnostics Market: estimated at USD 52.7 million in 2025, accounting for 14.2% share and advancing at a CAGR of 4.9%, benefits from precision diagnostics and biosafety-grade molecular laboratories for rapid testing of imported and wildlife rabies cases.
• South Korea: South Korea’s Rabies Diagnostics Market: valued at USD 33.4 million in 2025, capturing 9.0% share and increasing at a CAGR of 5.0%, is driven by domestic production of diagnostic kits and integration of rabies testing within broader zoonotic monitoring systems.
• Indonesia: Indonesia’s Rabies Diagnostics Market: projected at USD 31.1 million in 2025, holding 8.3% share and growing at a CAGR of 5.3%, benefits from government-backed diagnostic accessibility projects targeting 34 provinces under national rabies control initiatives.

MIDDLE EAST & AFRICA

Middle East & Africa contributes roughly 12% of global rabies diagnostics volumes in 2024 despite high exposure risks. In Africa alone, more than 25 000 diagnostic samples were processed in national labs in 2023 and mobile field campaigns distributed over 8,000 rapid kits in rural zones, improving remote coverage by about 19% compared to 2021. In Gulf Cooperation Council countries, diagnostic laboratory upgrades increased rabies test capacity by nearly 17% in 2023.

The Middle East & Africa Rabies Diagnostics Market: estimated at USD 218.5 million in 2025, representing 11.7% global share and growing at a CAGR of 4.4%, is driven by expanding veterinary diagnostics, government vaccination campaigns, and WHO-supported rabies surveillance programs.

Middle East & Africa – Major Dominant Countries in the Rabies Diagnostics Market

• South Africa: South Africa leads the region with a market size of USD 63.2 million in 2025, capturing 28.9% share and increasing at a CAGR of 4.5%, driven by over 300 diagnostic facilities integrating rapid immunoassays and PCR-based rabies testing for wildlife and domestic animals.
• Saudi Arabia: Saudi Arabia’s Rabies Diagnostics Market: valued at USD 44.8 million in 2025, representing 20.5% share and expanding at a CAGR of 4.3%, benefits from modernized veterinary laboratories and animal surveillance systems improving nationwide diagnostic response times.
• United Arab Emirates: The UAE’s Rabies Diagnostics Market: estimated at USD 31.7 million in 2025, holding 14.5% share and growing at a CAGR of 4.4%, is supported by robust healthcare infrastructure integrating zoonotic testing into veterinary hospital systems.
• Egypt: Egypt’s Rabies Diagnostics Market: valued at USD 28.9 million in 2025, representing 13.2% share and increasing at a CAGR of 4.2%, is fueled by national diagnostic programs expanding across 27 governorates with WHO collaboration.
• Kenya: Kenya’s Rabies Diagnostics Market: projected at USD 24.2 million in 2025, capturing 11.1% share and advancing at a CAGR of 4.6%, benefits from the scaling of rural diagnostic centers providing ELISA and rapid rabies test kits under national elimination goals.

List of Top Rabies Diagnostics Companies

• BioNote, Inc
• Merck
• Thermo Fisher
• Techne
• Abbexa Ltd
• QIAGEN
• Creative Diagnostics
• Fluidigm
• Express Biotech International
• Demeditec Diagnostics GmbH
• Aviva Systems Biology
• Roche
• Bio-Rad Laboratories
• Agilent
• BioMerieux
• Norgen Biotek Corp

Top Two Companies with Highest Market Share

• Bio-Rad Laboratories: holds approximately 18% of the global Rabies Diagnostics Market share in 2024, supplying more than 120,000 rabies test kits annually for human and animal health applications.
• Merck: controls about 15% market share and delivered over 100,000 rabies diagnostic units worldwide in 2023, including multiplex ELISA and PCR solutions tailored for veterinary and public-health test labs.

Investment Analysis and Opportunities

Investment activity in the Rabies Diagnostics Market reached over USD 250 million in 2023 across new kit development, field-testing equipment and mobile diagnostics deployment. Diagnostic companies increased R&D expenditure by nearly 22% compared to 2021 to develop multiplex panels detecting rabies plus other zoonotic pathogens.

New Product Development

In the Rabies Diagnostics Market, over 45 new diagnostic products were launched globally between 2022-2024, of which approximately 41% were multiplex assays combining rabies detection with other viral pathogens. Portable rapid test kits deployed in more than 12 countries improved field diagnostics by reducing result time by nearly 17%.

Five Recent Developments

• A diagnostics firm shipped over 100,000 rabies ELISA test kits to African outreach programmes in 2024, increasing diagnostic coverage by approximately 24%.
• A U.S. company launched a multiplex PCR system in early 2025 that reduced rabies result turnaround time by 18% compared to standard protocols.
• A mobile diagnostics provider deployed 8,000+ field rapid rabies test kits across rural India in 2023, enabling mobile testing points and improving access in remote regions by approx. 21%.
• A veterinary diagnostics supplier entered a partnership in 2024 to distribute over 150,000 rapid test kits for canine rabies screening across Southeast Asia, increasing market presence by 15%.
• A research lab in Europe validated a next-generation portable rabies diagnostic kit in 2025, achieving sensitivity improvement of approximately 14% and reducing equipment footprint by nearly 30%.

Report Coverage of Rabies Diagnostics Market

This Rabies Diagnostics Market Research Report covers global market sizing, segmentation by type (ELISA, PCR, Others) and application (Hospitals, Diagnostic Centers, Public Health Labs, Home Care Settings) inclusive of over 25 countries and more than 8 regions. It incorporates unit volume data exceeding 400,000 tests annually in high-burden regions and profiles over 150 diagnostic products launched between 2020-2025.

Rabies Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1991.73 Million in 2026
Market Size Value By	USD 2952.12 Million by 2035
Growth Rate	CAGR of 4.47% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Enzyme-Linked Immunosorbent Assay (ELISA) Polymerase Chain Reaction (PCR) Assay Others By Application : Hospitals Diagnostic Centers Public Health Labs Home Care Setting
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample